Strengths and Weaknesses of TB Drug Management Democratic Republic of Congo, Congo Brazzaville, Uganda, Nigeria, and Benin
Group 1 Countries • Uganda • Democratic Republic of Congo • Congo Brazzaville • Nigeria • Benin Republic
Policy and Legal Framework: Strengths • NDP is present in all countries. In Congo Brazzaville, it is developed but not implemented. • Most countries have TB drugs on the EDL (except DRC). • Special consideration for donated drugs; all require evidence of quality control (+, -).
Policy and Legal Framework: Weaknesses • Weak enforcement of policies, also in the private sector • Labs for QC not adequate • DOTS not widespread (except Benin) • Government funding levels inadequate (except Benin)
Selection Process • All countries have protocols (STGs), however each country’s STGs may differ • Weakness: Forms and dosages differ within country • Regimen changes have been successful • Weakness: Problems with wastage
Distribution and Use • All NTP involved in quantification • Weakness: Data questionable (except Benin, CB) • Drug management information systems are sometimes weak • Movement of drugs from the central to the regional level works well • Weakness: Movement from the regional to peripheral level is a problem
Distribution and Use, continued • Use of blister packs has improved compliance and reduced wastage (Nigeria, Uganda)